This early-phase clinical trial is testing a new treatment called brenetafusp (IMC-F106C) for adults with advanced cancers that test positive for a specific protein called PRAME. Brenetafusp is a type of immunotherapy known as an ImmTAC®, which is designed to help the immune system find and destroy cancer cells. To take part in the trial, patients must also […]
This Phase 1/2, first-in-human, open-label, multicenter study aims to determine the safest and most effective dose (Maximum Tolerated Dose, MTD, or Recommended Phase 2 Dose, RP2D) of LNS8801, both on its own and in combination with pembrolizumab. Using a 3+3 dose escalation design, the study will evaluate the safety, tolerability, how the drug behaves in
This Phase 1/2a study, known as the TRESR Study, is investigating the safety, how the body processes and responds to the drug (pharmacokinetics and pharmacodynamics), and the early effectiveness of RP-3500 (camonsertib) in treating advanced solid tumours with specific genetic mutations. RP-3500 will be tested both on its own and in combination with talazoparib (a
Study of RP-3500, Camonsertib, in Advanced Solid Tumors Read More »
The researchers are doing this study to find out whether the combination of axitinib and nivolumab is an effective and safe treatment for people with advanced or metastatic mucosal melanoma that has not been treated before.
Axitinib and Nivolumab for the Treatment of Mucosal Melanoma Read More »
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
This Phase 1/2 multi-centre, open-label basket study aims to assess the safety and effectiveness of IDE196 in treating solid tumours with specific genetic changes, such as GNAQ or GNA11 mutations or PRKC fusions. The study includes patients with metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other types of solid tumours.
Phase 2 multi-center open-label IDE196 study in patients with primary uveal melanoma requiring either enucleation or plaque brachytherapy. Patients will be treated in neoadjuvant setting up to 6 months (or maximum benefit) followed by primary local therapy. An additional 6 months of adjuvant treatment to follow with long term follow-up (up to 3 years) to
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma Read More »
